Introduction {#sec1_1}
============

Intracerebral hemorrhage (ICH) is the cause of stroke in about 30--40% of stroke patients in Pakistan \[[@B1]\]. The hemorrhage volume is an important predictor of outcome in ICH patients \[[@B2]\], and it is well known that an increased hemorrhage volume in ICH patients is associated with increased functional disability and mortality. One study demonstrated that the predicted 30-day mortality was 93% for ICH volumes \>60 mm^3^, 64% for those from 30 to 60 mm^3^ and 19% for those \<30 mm^3^\[[@B3]\]. In another study, warfarin treatment in patients with INR \>3.0 was associated with larger ICH volumes \[[@B4]\]. Apart from anticoagulation, it is not well known why some patients have large-volume and others small-volume hemorrhage. Relationships between ICH volume and duration of hypertension, number and types of anti-hypertensive medications, drug compliance and blood pressure (BP) control 3--6 months prior to the ICH event have not been elucidated yet.

Identification of modifiable factors associated with large-volume hemorrhage in hypertensive patients may help to reduce morbidity and mortality related to ICH. Therefore, the objective of this study was to identify predictors of large-volume ICH in hypertensive patients.

Methods {#sec1_2}
=======

We prospectively analyzed 157 consecutive hypertensive patients admitted for ICH in 2008--2009 at the Aga Khan University, a tertiary care center in Karachi, Pakistan. Their ICH volumes were assessed using CT or MRI, and various factors, including duration of hypertension, medical treatment, compliance, co-morbidity, and hematologic and coagulation profiles, were determined. An ICH volume \>30 mm^3^ was defined as high-volume ICH, which was calculated using Broderick\'s method \[[@B3], [@B5]\].

Hypertension was defined as a history of hypertension, BP \>140 (systolic) and/or \>90 (diastolic) mm Hg on ≥3 measurements during hospitalization or treatment with anti-hypertensive drugs. Diabetes mellitus was defined as a history of diabetes mellitus and fasting serum glucose levels \>110 mg/dl, or treatment with insulin or hypoglycemic drugs. Dyslipidemia was defined as a fasting total blood cholesterol ≥200 mg/dl and/or LDL cholesterol ≥100 mg/dl and/or triglycerides ≥150 mg/dl. Patients smoking ≥10 cigarettes/day for \>10 years were classified as smokers. Patients or immediate family members were asked about the use of anti-hypertensive medications, compliance to these medications and quality of BP control at home prior to admission. Patients were regarded as non-compliant if they did not take half or more of their anti-hypertensive medication during the preceding month. BP control was classified as poor if BP was \>140 (systolic) and/or \>90 (diastolic) mm Hg on \>50% of home measurements despite taking anti-hypertensive medication during the 1-month period preceding the ICH event.

The χ^2^ test and Student\'s t test were used to compare both groups regarding baseline characteristics and outcome. Based on the findings in univariate analysis, a logistic regression model was built to identify predictors of high-volume ICH.

The study protocol was approved by the local ethical review committee of the hospital.

Results {#sec1_3}
=======

Of the 157 hypertensive patients with ICH analyzed, 133 patients were included in the study. We excluded 24 patients with brain stem, cerebellum and pure intraventricular hemorrhage, because the volume-outcome relationship of ICH in these brain areas could be different from basal-ganglia, thalamic or lobar ICH.

Mean age of the patients was 55 years (range 19--85 years), and 56 patients (70%) were male. Diagnosis of hypertension was known in 119 (89%) patients, while 14 (11%) were unaware of their diagnosis. Duration of hypertension was \>10 years in 56 (42%) patients. Only 81 patients (61%) were on any anti-hypertensive medication: 50 (38%) were treated with 1 anti-hypertensive drug while 31 (23%) were on ≥2 anti-hypertensive drugs. We were able to retrieve the history of compliance with anti-hypertensive medication for the 1-month period preceding ICH in 46 patients (35%), and 25 (19%) were poorly adherent to their medication.

Other co-morbidities included diabetes (23; 17%), dyslipidemia (11; 8%) and cigarette smoking (20; 15%). Anti-platelet medication was taken by 49 (37%) patients, while 8 (6%) patients were on warfarin.

CT scans were performed within 24 h of symptom onset in all patients. ICH were located in the basal ganglia and thalamus in 98 (74%) patients, and lobar ICH was noted in 35 (26%) patients. The mean ICH volume was 26 mm^3^ (range 8--96 mm^3^), ranging from 23 mm^3^ in basal ganglia/thalamus to 29 mm^3^ in lobar areas. This difference was not statistically significant (p = 0.09). ICH volume was \<30 mm^3^ in 86 (65%) patients, while 47 (35%) patients had high-volume ICH (\> 30 mm^3^). Mortality was significantly higher (32%) in patients with high-volume ICH compared to patients with low-volume ICH (6%).

Male gender (p = 0.005), use of warfarin (p = 0.05), INR \>3.0 on admission (p = 0.04), use of \>1 anti-hypertensive agent (p = 0.001) and poor compliance with medication (p = 0.001) were associated with large-volume ICH in univariate analysis (table [1](#T1){ref-type="table"}).

In multivariate analysis, predictors of large-volume ICH were use of \>1 anti-hypertensive agent and poor compliance (table [2](#T2){ref-type="table"}).

Discussion {#sec1_4}
==========

These findings indicate that more than one third of patients in this tertiary hospital referral setting had high-volume ICH, and use of ≥2 anti-hypertensive agents and poor compliance with anti-hypertensive medication were the strongest predictors of high-volume hemorrhage. Patients treated with ≥2 anti-hypertensive drugs most likely represent aggressive forms of hypertension, and non-compliance is probably associated with sustained uncontrolled BP. These findings may also be a sign of more careful management of hypertension (despite lesser compliance) by doctors. They may also suggest that during acute bleeding, the presence of more vasoplegic medication triggers a longer and more intense hemorrhage, or that a lower BP in the acute phase is associated with lower intracranial pressure (compared with patients with higher BP), resulting in prolonged and larger bleeding. Poor compliance with warfarin, in addition to anti-hypertensive medication, may be associated with an increased risk of hemorrhage.

Morbidity and mortality related to high-volume ICH could be reduced by interventions aiming to lower hemorrhage volume among these patients. It is well known from non-randomized subgroup evaluation in randomized trials (e.g. PROGRESS) and extrapolation from observation studies that aggressive BP control is associated with a lower incidence of ICH, suggesting that aggressive BP control may lead to smaller-volume hemorrhage with lower mortality. Our study confirms previous reports of a correlation between warfarin treatment and high INR and large-volume ICH \[[@B6]\].

A limitation of this study is its small number of study patients and limited available information regarding some aspects of BP control and medication compliance. Larger multicenter studies are required to confirm our findings.
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###### 

Predictors of high-volume (\>30 ml) hemorrhage in univariate analysis

  Patient characteristics                   Patients, n (%)   Odds ratio (95% confidence interval)   p value               
  ----------------------------------------- ----------------- -------------------------------------- --------------------- ---------
  Patients evaluated                        86 (65)           47 (35)                                                      
  Age \<60 years                            50 (58)           34 (72)                                0.53 (0.24--1.14)     0.10
  Male gender                               48 (55.8)         38 (80.9)                              3.34 (1.44--7.75)     0.005
  Duration of hypertension                                                                                                 
  \>10 years                                43 (50)           13 (27.7)                              0.39 (0.16--0.92)     0.07
  Anti-hypertensive treatment                                                                                              
  1 anti-hypertensive agent                 34 (40.5)         16 (35.6)                              0.39 (0.17--0.90)     0.069
  ≥2 anti-hypertensive agents               7 (8)             24 (51)                                14.92 (3.46--45.57)   \<0.001
  Poor compliance                           8 (9.3)           17 (36.2)                              10.09 (2.57--39.60)   0.001
  BP control                                                                                                               
  Regular home monitoring                   74 (86)           35 (74.5)                              0.47 (0.19--1.15)     0.10
  Poor during the last month                64 (74.4)         40 (85.1)                              0.50 (0.19--1.30)     0.15
  By a physician during the last 3 months   10 (11.6)         8 (17)                                 1.55 (0.57--4.26)     0.38
  Diabetes mellitus                         16 (19)           7 (15)                                 0.73 (0.35--1.96)     0.09
  Duration \> 10 years                      5 (6)             2 (4)                                  0.51 (0.22--0.97)     0.098
  Blood glucose \>150 mg/dl on admission    14 (16)           5 (10)                                 0.97 (0.35--2.13)     0.63
  Dyslipidemia                              8 (9)             3 (6)                                  0.55 (0.11--1.19)     0.11
  Statin treatment at home                  3 (4)             1 (2)                                  0.21 (0.09--0.87)     0.22
  Smoking status                            13 (15)           7 (15)                                 0.47 (0.11--1.25)     0.9
  Medication                                                                                                               
  Anti-platelets                            35 (41)           14 (30)                                1.02 (0.54--3.15)     0.06
  Warfarin                                  2 (2)             6 (13)                                 7.55 (1.24--19.55)    0.05
  Platelet count \<50,000 on admission      8 (9)             3 (6)                                  0.83 (0.31--2.01)     0.09
  INR \>3.0 on admission                    1                 5 (10)                                 10.50 (2.25--31.45)   0.04

###### 

Predictors of high-volume (\>30 ml) hemorrhage in multivariate analysis

  Patient characteristics                             Adjusted odds ratio (95% confidence interval)   p value
  --------------------------------------------------- ----------------------------------------------- ---------
  Male gender                                         2.85 (0.99--8.23)                               0.06
  Treatment with ≥2 anti-hypertensive agents          19.55 (3.01--54.43)                             0.002
  Poor compliance with anti-hypertensive medication   17.85 (3.17--43.86)                             0.005
  Warfarin use                                        9.67 (2.53--37.87)                              0.02
  INR \>3.0 on admission                              12.59 (2.94--44.89)                             0.01
